Delaware
|
04-2825458
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
incorporation)
|
Identification No.)
|
In response to its notification of Nasdaq, the Company received a Nasdaq Staff Deficiency Letter on October 26, 2007, confirming that the Company is no longer in compliance with Nasdaq's independent director and audit committee requirements.
Consistent with Marketplace Rules 4350(c)(1) and 4350(d)(4), and as confirmed by the Nasdaq Staff Deficiency Letter, Nasdaq will provide the Company with a cure period in order to regain compliance with the Marketplace Rules as follows:
* by the earlier of the Company's next annual shareholders' meeting or August 8, 2008; or
* if the next annual shareholders' meeting is held before February 4, 2008, then no later than February 4, 2008.
The Company is continuing its efforts at identifying a qualified replacement to fill the vacancies left by the departure of Mr. Neels and expects to complete this process and provide evidence of its compliance with the Marketplace Rules to Nasdaq no later than the expiration of the above cure period. If the Company fails to regain compliance within this period, its common stock is subject to delisting upon notification of such a determination by Nasdaq staff, which determination may be appealed.
On October 31, 2007, the Company issued a press release announcing the receipt of the Nasdaq Staff Deficiency Letter. A copy of the press release is included with this report as Exhibit 99.1 hereto and is incorporated herein by reference.
|
|
LeMaitre Vascular, Inc.
|
||||||
Date: October 31, 2007
|
By:
|
/s/ Christopher H. Martin
|
||||||
Christopher H. Martin
|
||||||||
Assistant Secretary
|
||||||||
Exhibit No.
|
Description
|
|
EX-99.1
|
Press Release dated October 31, 2007.
|